Modeling glioma growth and invasion in Drosophila melanogaster

Neoplasia

Volumn 11, Issue 9, 2009, Pages 882-888

  Witte, Hanna Teresa ^a,b   Jeibmann, Astrid ^a,b   Klämbt, Christian ^a   Paulus, Werner ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEFITINIB; INSULIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR GAL4; TRICIRIBINE; TYROSINE KINASE RECEPTOR; VASCULOTROPIN RECEPTOR; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL COUNT; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DROSOPHILA MELANOGASTER; GENE CONTROL; GENE OVEREXPRESSION; GLIA; GLIA CELL; GLIOMA; HUMAN; IMAGINAL DISC; LARVA; NONHUMAN; OPTIC DISK; OPTIC NERVE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; BRAIN NEOPLASMS; DROSOPHILA MELANOGASTER; EYE; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 69249155013     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09576     Document Type: Article

References (39)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, and Kleihues P (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97-109.
2. Colman H and Aldape K (2008). Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol 65, 877-883.
3. Mason WP and Cairncross JG (2008). Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas. Neurology 71, 365-373.
4. Reilly KM, Rubin JB, Gilbertson RJ, Garbow JR, Roussel MF, and Gutmann DH (2008). Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop. Cancer Res 68, 5508-5511.
5. Maddison K and Clarke AR (2005). New approaches for modelling cancer mechanisms in the mouse. J Pathol 205, 181-193.
6. Holland EC (2001). Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2, 120-129.
7. Jeibmann A and Paulus W (2009). Drosophila melanogaster as a model organism of brain diseases. Int J Mol Sci 10, 407-440.
8. Manev H, Dimitrijevic N, and Dzitoyeva S (2003). Techniques: fruit flies as models for neuropharmacological research. Trends Pharmacol Sci 24, 41-43.
9. Kang HL, Benzer S, and Min KT (2002). Life extension in Drosophila by feeding a drug. Proc Natl Acad Sci USA 99, 838-843.
10. Dzitoyeva S, Dimitrijevic N, and Manev H (2001). Intra-abdominal injection of double-stranded RNA into anesthetized adult Drosophila triggers RNA interference in the central nervous system. Mol Psychiatry 6, 665-670.
11. Nichols CD (2006). Drosophila melanogaster neurobiology, neuropharmacology, and how the fly can inform central nervous system drug discovery. Pharmacol Ther 112, 677-700.
12. Manev H and Dimitrijevic N (2004). Drosophila model for in vivo pharmacological analgesia research. Eur J Pharmacol 491, 207-208.
13. Ito N and Rubin GM (1999). gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell 96, 529-539.
14. Tapon N, Ito N, Dickson BJ, Treisman JE, and Hariharan IK (2001). The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105, 345-355.
15. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, Jafar-Nejad H, and Halder G (2006). The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8, 27-36.
16. The I, Hannigan GE, Cowley GS, Reginald S, Zhong Y, Gusella JF, Hariharan IK, and Bernards A (1997). Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276, 791-794.
17. Brumby AM and Richardson HE (2005). Using Drosophila melanogaster to map human cancer pathways. Nat Rev Cancer 5, 626-639.
18. Betschinger J, Mechtler K, and Knoblich JA (2006). Asymmetric segregation of the tumor suppressor brat regulates self-renewal in Drosophila neural stem cells. Cell 124, 1241-1253.
19. Klambt C, Hummel T, Granderath S, and Schimmelpfeng K (2001). Glial cell development in Drosophila. Int J Dev Neurosci 19, 373-378.
20. Silies M, Yuva Y, Engelen D, Aho A, Stork T, and Klambt C (2007). Glial cell migration in the eye disc. J Neurosci 27, 13130-13139.
21. Green P, Hartenstein AY, and Hartenstein V (1993). The embryonic development of the Drosophila visual system. Cell Tissue Res 273, 583-598.
22. Malpel S, Klarsfeld A, and Rouyer F (2002). Larval optic nerve and adult extraretinal photoreceptors sequentially associate with clock neurons during Drosophila brain development. Development 129, 1443-1453.
23. Paulus W, Witte H, Jeibmann A, and Klämbt C (2008). Modelling glioma growth and invasion in Drosophila. J Neuropathol Exp Neurol 67, 496-497.
24. Read RD, Cavenee WK, Furnari FB, and Thomas JB (2009). A Drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet 5, e1000374.
25. Sepp KJ, Schulte J, and Auld VJ (2001). Peripheral glia direct axon guidance across the CNS/PNS transition zone. Dev Biol 238, 47-63.
26. Queenan AM, Ghabrial A, and Schupbach T (1997). Ectopic activation of torpedo/Egfr, a Drosophila receptor tyrosine kinase, dorsalizes both the eggshell and the embryo. Development 124, 3871-3880.
27. Brand AH and Perrimon N (1993). Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118, 401-415.
28. Duchek P, Somogyi K, Jekely G, Beccari S, and Rorth P (2001). Guidance of cell migration by the Drosophila PDGF/VEGF receptor. Cell 107, 17-26.
29. Michelson AM, Gisselbrecht S, Zhou Y, Baek KH, and Buff EM (1998). Dual functions of the heartless fibroblast growth factor receptor in development of the Drosophila embryonic mesoderm. Dev Genet 22, 212-229.
30. Claes A, Idema AJ, and Wesseling P (2007). Diffuse glioma growth: a guerilla war. Acta Neuropathol 114, 443-458.
31. Oellers P, Schroer U, Senner V, Paulus W, and Thanos S (2009). Rocks are expressed in brain tumors and are required for glioma-cell migration on myelinated axons. Glia 57, 499-509.
32. Kita D, Yonekawa Y, Weller M, and Ohgaki H (2007). PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 113, 295-302.
33. Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
34. Rappl A, Piontek G, and Schlegel J (2008). EGFR-dependent migration of glial cells is mediated by reorganisation of N-cadherin. J Cell Sci 121, 4089-4097.
35. Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, Kratzke RA, Dudek A, Potter DA, Woo RA, O'Rourke DM, et al. (2008). Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther 7, 3586-3597.
36. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, et al. (2005). Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97, 880-887.
37. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353, 2012-2024.
38. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, et al. (2004). Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22, 133-142.
39. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287-290.